The 1975 Nobel laureate in Physiology/Medicine Prof. David Baltimore, from California Institute of Technology, California, USA, had reported in the July 8, 2014 Blood that: “Dual mechanisms by which MiR-125b represses IRF4 to induce myeloid ….leukemias.”
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Human Leukemias: NR2F2 suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4. This study suggests that NR2F2, by increasing the expression of its target gene, it could increase the expression of a number of tumor suppressor genes, including IRF4 and p53. Thereby, it could inhibit the progression of B-Cell and myeloid leukemias. Taken together, this study suggests that pharmacological formulations encompassing “NR2F2 or its activators” can be used to inhibit B-Cell and myeloid leukemias.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L., Molecular therapy for Human Leukemias: NR2F2 suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4, 7/October/2014, 14.40, Genome-2-Bio-Medicine Discovery Center.
Courtesy: When you cite drop us a line at firstname.lastname@example.org
* Research cooperation